



Applicant's Docket No. MPI00-557P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Chiang, Lillian Wei-Ming		
Application No.:	10/047,855	Group No.:	1642
Filed:	January 15, 2002	Examiner:	Holleran, Anne L.
For:	NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ **After** three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but **before** the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: June 6, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MIP00-557P1RM**

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00


**METHOD OF PAYMENT OF FEE**

4. ☐ Attached is a check in the amount of \$ \_\_\_\_\_ .
- ☐ Charge Account No. 501668 in the amount of \$0.00 .
- ☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

June 6, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By   
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-557P1RM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Chiang, Lillian Wei-Ming		
Application No.:	10/047,855	Group No.:	1642
Filed:	January 15, 2002	Examiner:	Holleran, Anne L.
For:	NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements;
2. ☒ Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449);
3. ☒ Copies of Listed Information Items Accompanying This Statement (Citation Nos. A4-A7, B4-B7)

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

- ☒ with sufficient postage as first class mail.

**37 C.F.R. SECTION 1.10\***


- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: June 6, 2005

  
Sean Hunziker  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.


The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copy of items (A4-A7, B4-B7) listed in Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

June 6, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By:   
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-557P1RM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Chiang, Lillian Wei-Ming		
Application No.:	10/047,855	Group No.:	1642
Filed:	January 15, 2002	Examiner:	Holleran, Anne L.
For:	NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF		

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY**

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier  
Limited Recognition Under 37 CFR §11.9(b)  
Customer Number 30405 or  
Millennium Pharmaceuticals, Inc.  
40 Landsdowne Street  
Cambridge, MA 02139

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: June 6, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**This is not a Power of Attorney to the above-named practitioner.**

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.


Please continue to forward all written and telephonic communications to Tracy M. Sioussat at the address and telephone number listed below.

**SIGNATURE of Practitioner of Record**

June 6, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By 

Tracy M. Sioussat

Attorney/Agent for Applicant

Reg. No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone: (617) 374-7679

Facsimile - (617) 551-8820


Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 5px 0;">(use as many sheets as necessary)</p>				<b>Complete if Known</b>		
Application Number		10/047,855				
Filing Date		January 15, 2002				
First Named Inventor		Chiang, Lillian Wei-Ming				
Group Art Unit		1642				
Examiner Name		Holleran, Anne L.				
Attorney Docket Number		MPI00-557P1RM				
Sheet	1	of	1			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number      Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A4	EPO	EP 1 074 617	A2	Helix Research Institute	02-07-2001	Pages 1-4, 102, 127-153, 155, 167-171, 173-178, 184, 189, 197-198, 218, 283, 376, 383, 413-414, 417, 421, 547, 580 752, 795-796, 939, 975-976, 1008, 1106, 1313, 1365-1366, 1491, 1541, 1553, 1574, 1580-1582, 1721, 1754, 1883, 1912-1913, 2029, 2057, 2153, 2175, 2256, 2276, 2304, 2452-2545, SEQ ID NO: 12778 & 12779, Internal Reference: PLACE 1005261.	
	A5	PCT	WO 01/70979	A2	Millennium Predictive Medicine, Inc.	09-27-2001	Entire document.	
	A6	PCT	WO 01/60860	A2	Millennium Predictive Medicine, Inc.	08-23-2001	Entire document.	
	A7	PCT	WO 01/74836	A1	Hyseq, Inc.	10-11-2001	Entire document.	

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
		Application Number	10/047,855		
		Filing Date	January 15, 2002		
		First Named Inventor	Chiang, Lillian Wei-Ming		
		Group Art Unit	1642		
		Examiner Name	Holleran, Anne L.		
		Attorney Docket Number	MPI00-557PIRM		
Sheet	1	of	1		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T 2
	B4	OTA, T., et al., "Homo Sapiens cDNA FLJ11085 fis, Clone PLACE1005261," created February 22, 2000, (sequence), EMBL Database [online], Hinxton, Cambridge, U.K., European Bioinformatics Institute, [retrieved on June 3, 2005]. Retrieved from the Internet: URL: <a href="http://www.ebi.ac.uk/embl/">http://www.ebi.ac.uk/embl/</a> . EMBL Accession No. AK001947.		
	B5	ADACHI, J., et al., "Mus Musculus Adult Male Tongue cDNA, RIKEN Full-Length Enriched Library, Clone: 2310032D16 Product:Hypothetical Glycerophosphoryl Diester Phosphodiesterase/Glycosyl Hydrolase, Starch-Binding Domain Containing Protein, Full Insert Sequence," created February 8, 2001, (sequence), EMBL Database [online], Hinxton, Cambridge, U.K., European Bioinformatics Institute, [retrieved on June 3, 2005]. Retrieved from the Internet: URL: <a href="http://www.ebi.ac.uk/embl/">http://www.ebi.ac.uk/embl/</a> . EMBL Accession No. AK009563.		
	B6	OHARA, O., et al., "Homo Sapiens mRNA for KIAA1434 Protein, Partial Cds," March 14, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on June 3, 2005]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</a> . GenBank Accession No. AB037855.		
	B7	NAGASE, T. et al, "Prediction of the Coding Sequences of Unidentified Human Genes. XVI. The Complete Sequences of 150 New cDNA Clones from Brain Which Code for Large Proteins In Vitro," <i>DNA Research</i> , Vol. 7, No. 1, (February 28, 2000), pp. 65-73.		

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.